SCHEMBL400102

SCHEMBL400102

O=C(c1cccc2ccccc12)C(Br)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.58
NR4A2 P43354 1/20 0.58
NR4A3 Q92570 1/20 0.58
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
PTPN1 P18031 1/20 0.51
CDC25B P30305 1/20 0.51
MMP3 P08254 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
PLK1 P53350 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
PTK2B Q14289 1/20 0.46
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099062 0.78 NR4A1 (0.57) NR4A1NR4A2NR4A3PTPN1CDC25B
SCHEMBL7440685 0.77 ALDH1A1 (0.53) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL4109121 0.75 NR4A1 (0.53) NR4A1NR4A2NR4A3PTPN1CDC25B
SCHEMBL1164084 0.75 NR4A1 (0.63) NR4A1NR4A2NR4A3PTPN1CDC25B
Naphthoic Acid SCHEMBL29352220 0.74 NR4A1 (1.00) NR4A1NR4A2NR4A3PTPN1CDC25B
Naphthoic Acid SCHEMBL28110155 0.74 NR4A1 (1.00) NR4A1NR4A2NR4A3PTPN1CDC25B
Naphthoic Acid SCHEMBL30233567 0.74 NR4A1 (1.00) NR4A1NR4A2NR4A3PTPN1CDC25B
Naphthoic Acid SCHEMBL17258 0.74 NR4A1 (1.00) NR4A1NR4A2NR4A3PTPN1CDC25B
SCHEMBL4114028 0.74 PTPN1 (0.54) NR4A1NR4A2NR4A3PTPN1CDC25B
SCHEMBL1428203 0.74 CES2 (0.50) CES2CES1L3MBTL1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101580-B2 Therapeutic agent for irritable bowel syndrome ASTELLAS PHARMA INC. (JP) 2012-01-24 US disclosed
US-20090093415-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME ASTELLAS PHARMA INC. (JP) 2009-04-09 US disclosed
EP-1872795-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME Astellas Pharma Inc. (JP) 2008-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093415-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME BRS3, VIPR2, BDKRB2 NR4A1 4083/4885NR4A2 1614/4885NR4A3 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.